Merck & Co., Inc. (MRK) KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery